Published in J Clin Invest on June 01, 2013
The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers. Cancer Cell (2015) 1.61
ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis. Cell Stem Cell (2016) 1.50
Adenosine-to-inosine RNA editing and human disease. Genome Med (2013) 1.40
Ascorbic acid improves pluripotency of human parthenogenetic embryonic stem cells through modifying imprinted gene expression in the Dlk1-Dio3 region. Stem Cell Res Ther (2015) 1.38
Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nat Cell Biol (2015) 1.36
Pathways and therapeutic targets in melanoma. Oncotarget (2014) 1.17
miRNA biogenesis: biological impact in the development of cancer. Cancer Biol Ther (2014) 1.13
Integrated RNA and DNA sequencing improves mutation detection in low purity tumors. Nucleic Acids Res (2014) 1.05
Strong reduction of AGO2 expression in melanoma and cellular consequences. Br J Cancer (2013) 1.02
Genomic analysis of ADAR1 binding and its involvement in multiple RNA processing pathways. Nat Commun (2015) 0.99
Dysregulation of microRNA biogenesis in cancer: the impact of mutant p53 on Drosha complex activity. J Exp Clin Cancer Res (2016) 0.94
ADAR1 is required for differentiation and neural induction by regulating microRNA processing in a catalytically independent manner. Cell Res (2015) 0.87
Dysregulation of microRNA biogenesis machinery in cancer. Crit Rev Biochem Mol Biol (2015) 0.86
Downregulation of miR-432 activates Wnt/β-catenin signaling and promotes human hepatocellular carcinoma proliferation. Oncotarget (2015) 0.86
ADAR mediates differential expression of polycistronic microRNAs. Nucleic Acids Res (2014) 0.85
The Period protein homolog LIN-42 negatively regulates microRNA biogenesis in C. elegans. Dev Biol (2014) 0.83
The emerging role of RNA editing in plasticity. J Exp Biol (2015) 0.83
Altered RNA editing in 3' UTR perturbs microRNA-mediated regulation of oncogenes and tumor-suppressors. Sci Rep (2016) 0.82
miR-17 regulates melanoma cell motility by inhibiting the translation of ETV1. Oncotarget (2015) 0.81
A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme. Oncotarget (2015) 0.79
Five novel mutations in the ADAR1 gene associated with dyschromatosis symmetrica hereditaria. BMC Med Genet (2014) 0.79
Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex. Open Biol (2014) 0.79
Identification of FLOT2 as a novel target for microRNA-34a in melanoma. J Cancer Res Clin Oncol (2014) 0.79
SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells. Oncotarget (2016) 0.78
Regulation of miRNA processing and miRNA mediated gene repression in cancer. Microrna (2014) 0.75
Functions of the RNA Editing Enzyme ADAR1 and Their Relevance to Human Diseases. Genes (Basel) (2016) 0.75
Aberrant overexpression of ADAR1 promotes gastric cancer progression by activating mTOR/p70S6K signaling. Oncotarget (2016) 0.75
Regulatory factors governing adenosine-to-inosine (A-to-I) RNA editing. Biosci Rep (2015) 0.75
ADAR1 and MicroRNA; A Hidden Crosstalk in Cancer. Int J Mol Sci (2017) 0.75
The integrated analysis of RNA-seq and microRNA-seq depicts miRNA-mRNA networks involved in Japanese flounder (Paralichthys olivaceus) albinism. PLoS One (2017) 0.75
Prediction of mammalian microRNA targets. Cell (2003) 53.70
Widespread changes in protein synthesis induced by microRNAs. Nature (2008) 31.44
MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol (2005) 18.94
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08
The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet (2010) 15.87
Systematic identification of abundant A-to-I editing sites in the human transcriptome. Nat Biotechnol (2004) 7.61
Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. Nat Struct Mol Biol (2005) 7.49
Redirection of silencing targets by adenosine-to-inosine editing of miRNAs. Science (2007) 7.15
Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell (2008) 6.84
Functions and regulation of RNA editing by ADAR deaminases. Annu Rev Biochem (2010) 5.99
The MC-Fold and MC-Sym pipeline infers RNA structure from sequence data. Nature (2008) 5.67
miR-21: a small multi-faceted RNA. J Cell Mol Med (2009) 5.59
A search for conserved sequences in coding regions reveals that the let-7 microRNA targets Dicer within its coding sequence. Proc Natl Acad Sci U S A (2008) 5.11
Imprinted microRNA genes transcribed antisense to a reciprocally imprinted retrotransposon-like gene. Nat Genet (2003) 4.68
Improved northern blot method for enhanced detection of small RNA. Nat Protoc (2008) 4.47
Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene. J Biol Chem (2003) 3.93
Phosphorylation of the human microRNA-generating complex mediates MAPK/Erk signaling. Cell (2009) 3.90
RNA editing of the microRNA-151 precursor blocks cleavage by the Dicer-TRBP complex. EMBO Rep (2007) 3.40
Editor meets silencer: crosstalk between RNA editing and RNA interference. Nat Rev Mol Cell Biol (2006) 3.31
mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol (2010) 3.15
Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res (2010) 3.02
Genomic imprinting at the mammalian Dlk1-Dio3 domain. Trends Genet (2008) 2.92
Frequency and fate of microRNA editing in human brain. Nucleic Acids Res (2008) 2.77
let-7 regulates Dicer expression and constitutes a negative feedback loop. Carcinogenesis (2008) 2.75
ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling. Nat Immunol (2008) 2.70
The many roles of an RNA editor. Nat Rev Genet (2001) 2.55
Proteins binding to duplexed RNA: one motif, multiple functions. Trends Biochem Sci (2000) 2.47
Altered adenosine-to-inosine RNA editing in human cancer. Genome Res (2007) 2.38
Mutagenic analysis of double-stranded RNA adenosine deaminase, a candidate enzyme for RNA editing of glutamate-gated ion channel transcripts. J Biol Chem (1995) 2.27
Evolutionarily conserved human targets of adenosine to inosine RNA editing. Nucleic Acids Res (2005) 1.96
ADAR gene family and A-to-I RNA editing: diverse roles in posttranscriptional gene regulation. Prog Nucleic Acid Res Mol Biol (2005) 1.78
Editing independent effects of ADARs on the miRNA/siRNA pathways. EMBO J (2009) 1.76
The NF90-NF45 complex functions as a negative regulator in the microRNA processing pathway. Mol Cell Biol (2009) 1.71
Down-regulation of RNA editing in pediatric astrocytomas: ADAR2 editing activity inhibits cell migration and proliferation. J Biol Chem (2008) 1.71
Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral. Virology (2011) 1.62
ADAR1 interacts with NF90 through double-stranded RNA and regulates NF90-mediated gene expression independently of RNA editing. Mol Cell Biol (2005) 1.49
De-repression of CTGF via the miR-17-92 cluster upon differentiation of human glioblastoma spheroid cultures. Oncogene (2010) 1.47
Adenosine deaminases acting on RNA (ADARs): RNA-editing enzymes. Genome Biol (2004) 1.41
Systematic identification of edited microRNAs in the human brain. Genome Res (2012) 1.35
Overexpression of dicer as a result of reduced let-7 MicroRNA levels contributes to increased cell proliferation of oral cancer cells. Genes Chromosomes Cancer (2010) 1.27
The Zalpha domain from human ADAR1 binds to the Z-DNA conformer of many different sequences. Nucleic Acids Res (1998) 1.21
A-to-I RNA editing: the "ADAR" side of human cancer. Semin Cell Dev Biol (2011) 1.19
RNA-regulated interaction of transportin-1 and exportin-5 with the double-stranded RNA-binding domain regulates nucleocytoplasmic shuttling of ADAR1. Mol Cell Biol (2009) 1.18
DNA hypermethylation as a chemotherapy target. Cell Signal (2011) 1.18
Adenosine-to-inosine RNA editing meets cancer. Carcinogenesis (2011) 1.17
Adenosine deaminases acting on RNA, RNA editing, and interferon action. J Interferon Cytokine Res (2010) 1.11
A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD). Leuk Res (2007) 1.09
RNA regulation and cancer development. Cancer Lett (2006) 1.08
Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS One (2011) 1.07
ADAR1 is required for hematopoietic progenitor cell survival via RNA editing. Proc Natl Acad Sci U S A (2009) 1.07
Human BLCAP transcript: new editing events in normal and cancerous tissues. Int J Cancer (2010) 1.04
Systemic dysregulation of CEACAM1 in melanoma patients. Cancer Immunol Immunother (2010) 1.02
Epigenetic regulation of miRNA genes in acute leukemia. Leukemia (2011) 1.02
Adenosine deaminase ADAR1 increases gene expression at the translational level by decreasing protein kinase PKR-dependent eIF-2alpha phosphorylation. J Mol Biol (2009) 0.96
Modulation of microRNA expression and function by ADARs. Curr Top Microbiol Immunol (2012) 0.94
Adenosine-to-inosine RNA editing. Wiley Interdiscip Rev Syst Biol Med (2010) 0.92
A new function for the RNA-editing enzyme ADAR1. Nat Immunol (2009) 0.91
A-to-I RNA editing: a new regulatory mechanism of global gene expression. Blood Cells Mol Dis (2007) 0.91
Abnormal expression of ADAR1 isoforms in Chinese pediatric acute leukemias. Biochem Biophys Res Commun (2011) 0.85
Characterization of ADAR1-mediated modulation of gene expression. Biochem Biophys Res Commun (2008) 0.82
p150 ADAR1 isoform involved in maintenance of HeLa cell proliferation. BMC Cancer (2006) 0.80
WHO-EORTC classification for cutaneous lymphomas. Blood (2005) 12.14
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Identification of cells initiating human melanomas. Nature (2008) 8.28
Systematic identification of abundant A-to-I editing sites in the human transcriptome. Nat Biotechnol (2004) 7.61
MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol (2008) 7.27
Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature (2012) 7.00
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med (2009) 5.50
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell (2006) 4.68
A module of negative feedback regulators defines growth factor signaling. Nat Genet (2007) 4.35
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell (2012) 4.04
NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med (2007) 3.99
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res (2004) 3.63
Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol (2009) 3.47
Leukemia cutis. Am J Clin Pathol (2008) 3.38
Directed differentiation of human embryonic stem cells into functional retinal pigment epithelium cells. Cell Stem Cell (2009) 3.09
Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res (2003) 3.07
miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res (2009) 3.07
Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res (2010) 3.02
A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nat Cell Biol (2007) 2.85
Rab38 and Rab32 control post-Golgi trafficking of melanogenic enzymes. J Cell Biol (2006) 2.79
STIM1 mutation associated with a syndrome of immunodeficiency and autoimmunity. N Engl J Med (2009) 2.72
PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell (2008) 2.66
Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant (2006) 2.63
Focus on bladder cancer. Cancer Cell (2004) 2.59
Functions of adaptor protein (AP)-3 and AP-1 in tyrosinase sorting from endosomes to melanosomes. Mol Biol Cell (2005) 2.56
Global dynamics of proteins: bridging between structure and function. Annu Rev Biophys (2010) 2.55
Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol (2005) 2.55
Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci U S A (2002) 2.53
Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med (2010) 2.47
Altered adenosine-to-inosine RNA editing in human cancer. Genome Res (2007) 2.38
Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol (2002) 2.35
Is abundant A-to-I RNA editing primate-specific? Trends Genet (2005) 2.32
Whole-slide imaging digital pathology as a platform for teleconsultation: a pilot study using paired subspecialist correlations. Arch Pathol Lab Med (2009) 2.30
Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience. J Urol (2005) 2.25
Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management. J Am Acad Dermatol (2005) 2.22
Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res (2009) 2.21
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer (2009) 2.20
LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J (2004) 2.20
Cell-specific ATP7A transport sustains copper-dependent tyrosinase activity in melanosomes. Nature (2008) 2.15
Use of p63 expression in distinguishing primary and metastatic cutaneous adnexal neoplasms from metastatic adenocarcinoma to skin. J Cutan Pathol (2007) 2.14
BLOC-1 is required for cargo-specific sorting from vacuolar early endosomes toward lysosome-related organelles. Mol Biol Cell (2006) 2.11
p16(Ink4a) in melanocyte senescence and differentiation. J Natl Cancer Inst (2002) 2.09
Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cutan Pathol (2012) 2.08
Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther (2003) 2.08
The performance of MelaFind: a prospective multicenter study. Arch Dermatol (2010) 2.07
Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell (2007) 2.03
Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis (2004) 2.03
Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J Hepatol (2011) 2.02
Case records of the Massachusetts General Hospital. Case 23-2014. A 41-year-old man with fevers, rash, pancytopenia, and abnormal liver function. N Engl J Med (2014) 2.00
Distinct clinical phenotypes associated with a mutation in the mitochondrial translation elongation factor EFTs. Am J Hum Genet (2006) 1.97
Integrative genome comparison of primary and metastatic melanomas. PLoS One (2010) 1.97
Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol (2002) 1.96
Evolutionarily conserved human targets of adenosine to inosine RNA editing. Nucleic Acids Res (2005) 1.96
A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood (2006) 1.94
An oncogenic role for ETV1 in melanoma. Cancer Res (2010) 1.94
Cell-replacement therapy for diabetes: Generating functional insulin-producing tissue from adult human liver cells. Proc Natl Acad Sci U S A (2005) 1.93
Transcriptome-wide mapping of N(6)-methyladenosine by m(6)A-seq based on immunocapturing and massively parallel sequencing. Nat Protoc (2013) 1.91
MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol (2008) 1.90
Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. Mol Cell (2011) 1.89
Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest (2008) 1.87
MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. Biochem Biophys Res Commun (2008) 1.85
Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol (2004) 1.84
Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet (2012) 1.81
A-to-I RNA editing occurs at over a hundred million genomic sites, located in a majority of human genes. Genome Res (2013) 1.81
Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle (2011) 1.80
Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest. Clin Cancer Res (2005) 1.80
Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood (2003) 1.80
Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res (2010) 1.78
TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology (2012) 1.78
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer (2004) 1.78
Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One (2012) 1.76
Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther (2003) 1.76
Mortality risk from squamous cell skin cancer. J Clin Oncol (2005) 1.74